Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$2.92 +1.0%	$2.69	$1.84 ▼ $5.31	$149.23M	1.3	704,745 shs	1.54 million shs
CBIO Crescent Biopharma	$15.06 +4.6%	$13.90	$10.83 ▼ $63.00	$294.42M	1.51	101,376 shs	44,912 shs
VNDA Vanda Pharmaceuticals	$4.75 +5.3%	$4.61	$3.81 ▼ $5.55	$280.67M	0.72	554,926 shs	340,378 shs
XOMA XOMA Royalty	$34.20 +4.4%	$27.20	$18.35 ▼ $35.00	$413.41M	1	46,803 shs	111,643 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	+1.04%	+14.51%	+6.96%	-3.95%	-34.23%
CBIO Crescent Biopharma	+4.58%	+9.21%	+14.26%	-98.04%	-98.04%
VNDA Vanda Pharmaceuticals	+5.32%	+8.94%	-1.86%	+9.70%	-12.04%
XOMA XOMA Royalty	+4.43%	+9.02%	+31.89%	+37.63%	+17.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHV Achieve Life Sciences	2.2652 of 5 stars	3.8	2.0	0.0	2.7	0.0	0.6
CBIO Crescent Biopharma	4.0009 of 5 stars	4.7	0.0	3.7	3.4	1.7	0.6
VNDA Vanda Pharmaceuticals	4.4049 of 5 stars	3.8	2.0	4.2	1.7	2.5	1.3
XOMA XOMA Royalty	4.2222 of 5 stars	3.3	4.0	3.0	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHV Achieve Life Sciences	3.50	Strong Buy	$14.67	402.28% Upside
CBIO Crescent Biopharma	3.40	Buy	$25.50	69.32% Upside
VNDA Vanda Pharmaceuticals	3.50	Strong Buy	$16.50	247.37% Upside
XOMA XOMA Royalty	2.67	Moderate Buy	$69.50	103.22% Upside

Current Analyst Ratings Breakdown

Latest ACHV, XOMA, CBIO, and VNDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	ACHV Achieve Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
8/21/2025	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/12/2025	XOMA XOMA Royalty	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/11/2025	CBIO Crescent Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
7/14/2025	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$27.00
6/25/2025	CBIO Crescent Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$28.00
6/20/2025	CBIO Crescent Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/18/2025	CBIO Crescent Biopharma	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$22.00
5/28/2025	XOMA XOMA Royalty	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$104.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	$0.82 per share	N/A
CBIO Crescent Biopharma	$10K	29,442.30	N/A	N/A	$6.92 per share	2.18
VNDA Vanda Pharmaceuticals	$203.47M	1.38	N/A	N/A	$8.23 per share	0.58
XOMA XOMA Royalty	$28.49M	14.51	N/A	N/A	$5.99 per share	5.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHV Achieve Life Sciences	-$39.83M	-$1.46	N/A	N/A	N/A	N/A	-193.49%	-116.68%	11/6/2025 (Estimated)
CBIO Crescent Biopharma	-$37.88M	-$34.93	N/A	N/A	N/A	N/A	-106.06%	-86.60%	N/A
VNDA Vanda Pharmaceuticals	-$18.90M	-$1.13	N/A	N/A	N/A	-32.90%	-12.89%	-10.47%	11/5/2025 (Estimated)
XOMA XOMA Royalty	-$13.82M	-$1.55	N/A	N/A	N/A	-27.57%	2.63%	0.97%	11/6/2025 (Estimated)

Latest ACHV, XOMA, CBIO, and VNDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	XOMA XOMA Royalty	-$0.12	$0.48	+$0.60	$0.44	$9.39 million	$13.13 million
8/7/2025	Q2 2025	ACHV Achieve Life Sciences	-$0.37	-$0.37	N/A	-$0.37	N/A	N/A
7/31/2025	Q2 2025	VNDA Vanda Pharmaceuticals	-$0.34	-$0.46	-$0.12	-$0.46	$54.77 million	$52.59 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	N/A
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XOMA XOMA Royalty	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHV Achieve Life Sciences	0.21	6.64	6.64
CBIO Crescent Biopharma	N/A	9.21	9.21
VNDA Vanda Pharmaceuticals	N/A	3.25	3.23
XOMA XOMA Royalty	1.41	4.88	4.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHV Achieve Life Sciences	33.52%
CBIO Crescent Biopharma	75.19%
VNDA Vanda Pharmaceuticals	88.14%
XOMA XOMA Royalty	95.92%

Insider Ownership

Company	Insider Ownership
ACHV Achieve Life Sciences	3.00%
CBIO Crescent Biopharma	4.00%
VNDA Vanda Pharmaceuticals	10.00%
XOMA XOMA Royalty	9.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHV Achieve Life Sciences	20	51.10 million	49.57 million	Optionable
CBIO Crescent Biopharma	50	19.55 million	18.77 million	No Data
VNDA Vanda Pharmaceuticals	290	59.09 million	53.18 million	Optionable
XOMA XOMA Royalty	10	12.09 million	10.99 million	Optionable

ACHV, XOMA, CBIO, and VNDA Headlines

Recent News About These Companies

Xoma’s Strategic Acquisitions and Innovative Financial Strategies Drive Buy Rating

August 22 at 6:10 AM | tipranks.com

Mural Oncology and XOMA Royalty Corporation Announce Definitive Agreement for Acquisition of Mural Oncology

August 20 at 9:31 AM | quiverquant.comQ

Mural Oncology to be acquired by XOMA unit for up to $2.24/share in cash

August 20 at 9:11 AM | seekingalpha.com

Mural Oncology Enters Definitive Agreement for Acquisition by XOMA Royalty Corporation in Cash Deal Valued at Approximately $36.2 Million

August 20 at 8:51 AM | quiverquant.comQ

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

August 20 at 8:49 AM | globenewswire.com

Q3 EPS Estimates for XOMA Royalty Reduced by Leerink Partnrs

August 19, 2025 | marketbeat.com

Leerink Partnrs Expects Reduced Earnings for XOMA Royalty

August 19, 2025 | americanbankingnews.com

How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%

August 18, 2025 | zacks.com

Leerink Partnrs Raises Earnings Estimates for XOMA Royalty

August 17, 2025 | marketbeat.com

XOMA Royalty (NASDAQ:XOMA) Rating Increased to Hold at Zacks Research

August 17, 2025 | marketbeat.com

XOMA Royalty (NASDAQ:XOMA) Releases Earnings Results, Beats Estimates By $0.60 EPS

August 16, 2025 | marketbeat.com

XOMA Royalty Corporation Beat Analyst Profit Forecasts, And Analysts Have New Estimates

August 16, 2025 | finance.yahoo.com

LAVA Therapeutics Announces Acquisition by XOMA Corporation

August 14, 2025 | tipranks.com

Xoma Corp. Reports Strong Earnings Growth in 2025

August 14, 2025 | msn.com

LAVA Therapeutics Enters Agreement to Be Acquired by XOMA Royalty Corporation and Announces Discontinuation of LAVA-1266 Development

August 13, 2025 | quiverquant.comQ

Cautious Hold Rating on Xoma Amid Strategic Acquisitions and Uncertain Growth Outlook

August 13, 2025 | tipranks.com

XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates

August 13, 2025 | zacks.com

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

August 13, 2025 | globenewswire.com

XOMA Royalty Corporation: XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

August 11, 2025 | finanznachrichten.de

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

August 11, 2025 | finance.yahoo.com

XOMA Royalty (NASDAQ:XOMA) Upgraded to "Buy" at Wall Street Zen

August 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV, XOMA, CBIO, and VNDA Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

$2.92 +0.03 (+1.04%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.96 +0.04 (+1.37%)

As of 08/22/2025 07:56 PM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Crescent Biopharma NASDAQ:CBIO

$15.06 +0.66 (+4.58%)

As of 08/22/2025 04:00 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Vanda Pharmaceuticals NASDAQ:VNDA

$4.75 +0.24 (+5.32%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.65 -0.10 (-2.02%)

As of 08/22/2025 06:54 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

XOMA Royalty NASDAQ:XOMA

$34.20 +1.45 (+4.43%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$34.30 +0.10 (+0.31%)

As of 08/22/2025 04:01 PM Eastern

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time